The brief · 23 March 2026

The AI brief, 2026-03-23

Today, medical AI is learning to explain itself, and security now follows agents in motion rather than waiting for them at startup.

1 min read J / K to navigate

Under the radar

Insilico and ASKA Team Up to Hunt New Endometriosis Targets

Women's health remains a neglected corner of pharma R&D, with conditions like endometriosis and uterine fibroids affecting millions of patients without a satisfactory targeted treatment. Insilico Medicine is putting its target discovery platform to work for ASKA Pharmaceutical to try to change that. Whether this yields an actual drug candidate, rather than just a list of promising targets, remains to be seen.

practitioners › Insilico's PandaOmics will be used to identify targets for endometriosis, uterine fibroids, and adenomyosis, under a partnership announced March 23, 2026.

Insilico Medicine →

AI Now Explains Its Reasoning Behind Pancreatic Cancer Prognoses

Pancreatic cancer is often caught too late, and existing prognostic models function as black boxes that doctors struggle to justify to patients. This nationwide study tests explainable AI models that reveal which factors drive the calculation, not just a final score. Whether hospitals adopt it beyond the study remains to be seen.

practitioners › Nationwide study published in PLOS Digital Health on March 23, 2026, on personalized, explainable prognostic models for pancreatic cancer.

PLOS Digital Health →

HiddenLayer now secures your AI agents while they're running, not just at launch

Once deployed, AI agents act on their own, and until now security mostly stopped at the deployment stage. HiddenLayer adds continuous runtime monitoring that catches an agent going off-script or getting hijacked mid-operation. Worth a look if you're starting to connect agents to systems that actually matter.

practitioners › Three components available now: agent activity visibility, investigation/threat hunting, and detection with automatic blocking.

HiddenLayer →